References
- Lundberg L., Johannesson M., Silverdahl M., Hermansson C., Lindberg M. Health‐related quality of life in patients with psoriasis and atopic dermatitis measured with SF‐36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000; 80: 430–4
- Rapp S. R., Feldman S. R., Exum M. L., Fleischer A. B Jr., Reboussin D. M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41((3 Pt 1))401–7
- Goeckerman W. H. Treatment of psoriasis. Northwest Med 1925; 24: 229–31
- Goeckerman W. H. Treatment of psoriasis: continued observations on the use of crude coal tar and ultraviolet light. Arch Dermatol Syphil 1931; 24: 446–50
- Squire B. Chrysophanic acid ointment. Pharm J Trans 1876; 36: 489–90
- Squire B. Treatment of psoriasis by an ointment of chrysophanic acid. Br Med J 1876; 2: 819–20
- Stern R. S., PUVA Follow‐up Study. Inpatient hospital care for psoriasis: a vanishing practice in the United States. J Am Acad Dermatol 2003; 49: 445–50
- Feldman S. R., Garton R., Averett W., Balkrishnan R., Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother 2003; 4: 1525–33
- Vensel E., Hilley T., Trent J., Taylor J. R., Kirsner R. S., Kerdel F. A., et al. Sustained improvement of the quality of life of patients with psoriasis after hospitalization. J Am Acad Dermatol 2000; 43((5 Pt 1))858–60
- Chaudhari U., Romano P., Mulcahy L. D., Dooley L. T., Baker D. G., Gottlieb A. B. Efficacy and safety of infliximab monotherapy for plaque‐type psoriasis: a randomised trial. Lancet 2001; 357: 1842–7
- Rongioletti F., Borenstein M., Kirsner R., Kerdel F. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatol Treat 2003; 14: 222–5
- O'Quinn R. P., Miller J. L. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol 2002; 138: 644–8
- Newland M. R., Weinstein A., Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002; 41: 449–52
- Gordon K. B., Papp K. A., Hamilton T. K., Walicke P. A., Dummer W., Li N., , Efalizumab Study Group, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290: 3073–80
- Leonardi C. L., Powers J. L., Matheson R. T., Goffe B. S., Zitnik R., Wang A., , Etanercept Psoriasis Study Group, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014–22
- Lebwohl M., Christophers E., Langley R., Ortonne J. P., Roberts J., Griffiths C. E., Alefacept Clinical Study Group. An international, randomized, double‐blind, placebo‐controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719–27
- Cheifetz A., Smedley M., Martin S., Reiter M., Leone G., Mayer L., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 1315–24, 98